22. August 2018 Agena Announces MassARRAY® Technology Selected for Participation in CANCER-ID Consortium

Agena Bioscience, a global provider of molecular testing solutions, announced today that it has been selected for participation in the CANCER-ID Consortium. Agena’s MassARRAY® System will support mutation detection from liquid biopsy samples as part of the consortium’s key work packages in lung cancer and breast cancer. "We are honored to have been selected to participate in the CANCER-ID consortium" said Peter Dansky, Chief Executive Officer of Agena Bioscience. "With the MassARRAY System, we look forward to contributing the assay sensitivity, rapid workflow and low cost per test necessary to support the goals of the consortium in bringing liquid biopsy into personalized medicine." CANCER-ID is a European consortium supported by Europe's Innovative Medicines Initiative (IMI). With partners from 13 countries, the goal of the consortium is to establish standard protocols for and the clinical validation of the use of blood-based biomarkers for cancer. It brings together internationally recognized experts in CTC's, ctDNA and cfmiRNA who are committed to establishing clinical utility of liquid biopsy to monitor efficacy of treatment and potentially improve treatment options for patients with cancer. "The development of robust validated assays is required to bring liquid biopsy into the clinic", says Prof. Klaus Pantel from the University Medical Center Hamburg-Eppendorf and a Co-Coordinator of CANCER-ID. "From our experience, MassARRAY has the sensitivity necessary to pick up mutations that are relevant to therapeutic decisions in NSCLC patients." Source: Agena Bioscience Press Release from July 24th, 2018, http://agenabio.com/company/press-release/agena-announces-massarray-technology-selected-participation-cancer-id-consortium/